Yonesaka Kimio 米阪仁雄

… Alternative Names

米阪仁雄ヨネサカキミオ

YONESAKA Kimio 米阪仁雄

Less

Researcher Number	30330260
Other IDs
Affiliation (Current)	2025: 近畿大学, 医学部, 准教授
Affiliation (based on the past Project Information) *help	2022 – 2023: 近畿大学, 医学部, 准教授 2021: 近畿大学, 医学部, 講師 2019: 近畿大学, 医学部, 講師 2018: 近畿大学, 医学部附属病院, 講師 2017: 近畿大学, 医学部, 講師 2014 – 2016: 近畿大学, 医学部附属病院, 講師
Review Section/Research Field	Principal Investigator Basic Section 50020:Tumor diagnostics and therapeutics-related / Tumor diagnostics Except Principal Investigator Tumor therapeutics
Keywords	Principal Investigator MET / AKT / MEK / PTPRR / EGFR / ソトラシブ / KRAS / アファチニブ / ヘレグリン / HER3 / 薬効評価と予測 … More Except Principal Investigator … More 分子標的治療 / heregulin / 血漿検体 / SKBR-3 / N87 / cfDNA BC / WJOG7212G / 西日本がん研究機構 / ヘレギュリン / 薬剤耐性 / 分子標的薬 / 化学療法 / 胃癌 / 乳癌 / HER2 Less

Exploring mechanism underlying resistance to kras inhibitorPrincipal Investigator
- Principal Investigator
  
  米阪仁雄
- Project Period (FY)
  2021 – 2024
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 50020:Tumor diagnostics and therapeutics-related
- Research Institution
  Kindai University
Investigation for a mechanism of cetuxifmab resistance in head and neck cancersPrincipal Investigator
- Principal Investigator
  
  YONESAKA Kimio
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor diagnostics
- Research Institution
  Kindai University
A biomarker study of heregulin to predict efficacy of anti-HER2 drugs in HER2-positive breast and gastric cancer
- Principal Investigator
  
  TSURUTANI Junji
- Project Period (FY)
  2014 – 2016
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Research Field
  
  Tumor therapeutics
- Research Institution
  Kindai University

All 2023 2022 2021 2019 2018 2017 2016

All Journal Article Presentation Patent

[Journal Article] KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms2021
- Author(s)
  Suzuki Shinichiro、Yonesaka Kimio、Teramura Takeshi、Takehara Toshiyuki、Kato Ryoji、Sakai Hitomi、Haratani Koji、Tanizaki Junko、Kawakami Hisato、Hayashi Hidetoshi、Sakai Kazuko、Nishio Kazuto、Nakagawa Kazuhiko
- Journal Title
  
  Clinical Cancer Research
  
  Volume: 27 Issue: 20 Pages: 5697-5707
- DOI
  10.1158/1078-0432.ccr-21-0856
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-21K07204
[Journal Article] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer2019
- Author(s)
  Satomi Watanabe, Kimio Yonesaka, Junko Tanizaki, Yoshikane Nonagase, Naoki Takegawa, Koji Haratani, Hisato Kawakami, Hidetoshi Hayashi, Masayuki Takeda, Junji Tsurutani, Kazuhiko Nakagawa
- Journal Title
  
  Cancer Medicine
  
  Volume: 8 Issue: 3 Pages: 1258-1268
- DOI
  10.1002/cam4.1995
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification2019
- Author(s)
  Takegawa Naoki、Tsurutani Junji、Kawakami Hisato、Yonesaka Kimio、Kato Ryoji、Haratani Koji、Hayashi Hidetoshi、Takeda Masayuki、Nonagase Yoshikane、Maenishi Osamu、Nakagawa Kazuhiko
- Journal Title
  
  International Journal of Cancer
  
  Volume: 145 Issue: 12 Pages: 3414-3424
- DOI
  10.1002/ijc.32408
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-19K11730, KAKENHI-PROJECT-26430174
[Journal Article] Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI2019
- Author(s)
  Yonesaka Kimio、Tanaka Kaoru、Kitano Mutsukazu、Kawakami Hisato、Hayashi Hidetoshi、Takeda Masayuki、Sakai Kazuko、Nishio Kazuto、Doi Katsumi、Nakagawa Kazuhiko
- Journal Title
  
  Oncogenesis
  
  Volume: 8 Issue: 10 Pages: 1-10
- DOI
  10.1038/s41389-019-0164-9
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K07203
[Journal Article] Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer2018
- Author(s)
  Satomi Watanabe, Hidetoshi Hayashi, Koji Haratani, Shigeki Shimizu, Junko Tanizaki, Kazuko Sakai, Hisato Kawakami, Kimio Yonesaka, Junji Tsurutani, Yosuke Togashi, Kazuto Nishio, Akihiko Ito, Kazuhiko Nakagawa
- Journal Title
  
  Cancer Science
  
  Volume: 110 Issue: 1 Pages: 52-60
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance2017
- Author(s)
  Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa, Junji Tsurutani
- Journal Title
  
  International Journal of Cancer
  
  Volume: 141 Issue: 8 Pages: 1682-1689
- DOI
  10.1002/ijc.30870
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.2016
- Author(s)
  Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
- Journal Title
  
  Oncotarget
  
  Volume: 20;7(51) Issue: 51 Pages: 84860-84871
- DOI
  10.18632/oncotarget.12743
- Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-26430174
[Journal Article] HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer2016
- Author(s)
  Naoki Takegawa, Kimio Yonesaka, Kazuko Sakai, Hiroto Ueda, Satomi Watanabe, Yoshikane Nonagase, Tatsuya Okuno, Masayuki Takeda, Osamu Maenishi, Junji Tsurutani, Taroh Satoh, Isamu Okamoto, Kazuto Nishio, Takao Tamura, Kazuhiko Nakagawa
- Journal Title
  
  Oncotarget
  
  Volume: 7 Issue: 3 Pages: 3453-3460
- DOI
  10.18632/oncotarget.6498
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-26430174
[Patent] 癌治療用組成物2022
- Inventor(s)
  米阪仁雄、中川和彦、寺村岳士
- Industrial Property Rights Holder
  米阪仁雄、中川和彦、寺村岳士
- Industrial Property Rights Type
  特許
- Industrial Property Number
  2023-003798
- Filing Date
  2022
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] Combating acquired resistance to KRAS inhibitors in NSCLC by targeting PTPRR-mediated activation of EGFR signaling2023
- Author(s)
  Hiroaki Kanemura, Kimio Yonesaka
- Organizer
  日本癌学会
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] Met amplification confers resistance to KRAS inhibitors, but may be rare in de novo resistant non-small cell lung cancer2023
- Author(s)
  Shinichiro Suzuki, Kimio Yonesaka
- Organizer
  日本癌学会
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] 抗体薬物複合体による難治性腫瘍の治療戦略2023
- Author(s)
  米阪仁雄
- Organizer
  日本がん分子標的治療学会
- Invited
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] MET遺伝子増幅に依存した KRAS G12C遺伝子変異を有する非小細胞肺癌のRASあるいは非RASシグナルを介したKRAS阻害剤への耐性2022
- Author(s)
  鈴木慎一郎、米阪仁雄、坂井和子、西尾和人、中川和彦
- Organizer
  日本がん分子標的治療学会
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer2022
- Author(s)
  Shinichiro Suzuki, Kimio Yonesaka, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
- Organizer
  日本癌学会
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] MET遺伝子増幅によるソトラシブへの耐性2021
- Author(s)
  鈴木慎一郎　米阪仁雄
- Organizer
  第80回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-21K07204
[Presentation] Anti-EGFR antibody-resistant head and neck squamous cell carcinoma maintained sensitivity to pan-HER inhibitor2019
- Author(s)
  米阪仁雄
- Organizer
  日本がん分子標的治療学会
- Data Source
  KAKENHI-PROJECT-17K07203
[Presentation] Anti-EGFR antibody-resistant head and neck squamous cell carcinoma maintained sensitivity to pan-HER inhibitor2019
- Author(s)
  米阪仁雄
- Organizer
  日本臨床腫瘍学会
- Data Source
  KAKENHI-PROJECT-17K07203
[Presentation] heregulin発現HER2陽性乳癌・胃癌における抗HER2薬ラパチニブ、トラスツズマブ、T-DM1の感受性に関する研究2017
- Author(s)
  野長瀬祥兼, 米阪仁雄, 川上尚人, 渡邉諭美, 原谷浩司, 高濱隆幸, 武川直樹, 植田勲人, 谷崎潤子, 林秀敏, 吉田健史, 武田真幸, 千葉康敬, 田村孝雄, 中川和彦, 鶴谷純司
- Organizer
  第25回日本乳癌学会総会
- Data Source
  KAKENHI-PROJECT-26430174

1. TSURUTANI Junji (30319686)

# of Collaborated Projects: 1 results

# of Collaborated Products: 6 results
2. 中川和彦 (40298964)

# of Collaborated Projects: 1 results

# of Collaborated Products: 6 results
3. 坂井和子 (20580559)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
4. 土井勝美 (40243224)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
5. 北野睦三 (60716330)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
6. 田中薫 (80548628)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
7. 寺村岳士 (40460901)

# of Collaborated Projects: 1 results

# of Collaborated Products: 1 results
8. 鈴木慎一郎 (60823614)

# of Collaborated Projects: 1 results

# of Collaborated Products: 5 results
9. 前西修

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

Yonesaka Kimio 米阪 仁雄

米阪 仁雄 ヨネサカ キミオ

YONESAKA Kimio 米阪 仁雄

Research Projects

Research Products

Co-Researchers

Exploring mechanism underlying resistance to kras inhibitorPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Investigation for a mechanism of cetuxifmab resistance in head and neck cancersPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

A biomarker study of heregulin to predict efficacy of anti-HER2 drugs in HER2-positive breast and gastric cancer

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms2021

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer2018

Author(s)

Journal Title

Data Source

[Journal Article] DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance2017

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.2016

Author(s)

Journal Title

DOI

Data Source

[Journal Article] HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer2016

Author(s)

Journal Title

DOI

Data Source

[Patent] 癌治療用組成物2022

Inventor(s)

Industrial Property Rights Holder

Industrial Property Rights Type

Industrial Property Number

Filing Date

Data Source

[Presentation] Combating acquired resistance to KRAS inhibitors in NSCLC by targeting PTPRR-mediated activation of EGFR signaling2023

Author(s)

Organizer

Data Source

[Presentation] Met amplification confers resistance to KRAS inhibitors, but may be rare in de novo resistant non-small cell lung cancer2023

Author(s)

Organizer

Data Source

[Presentation] 抗体薬物複合体による難治性腫瘍の治療戦略2023

Author(s)

Yonesaka Kimio 米阪仁雄

米阪仁雄ヨネサカキミオ

YONESAKA Kimio 米阪仁雄